Tema ETFs LLC Acquires 9,933 Shares of Bristol Myers Squibb Company $BMY

Tema ETFs LLC increased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 6.4% during the second quarter, Holdings Channel reports. The fund owned 164,530 shares of the biopharmaceutical company’s stock after acquiring an additional 9,933 shares during the quarter. Tema ETFs LLC’s holdings in Bristol Myers Squibb were worth $9,480,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Bristol Myers Squibb by 59.4% during the second quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after acquiring an additional 2,786 shares during the last quarter. United Bank boosted its holdings in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after acquiring an additional 3,277 shares during the period. Marshall Wace LLP acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $221,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Bristol Myers Squibb in the second quarter valued at approximately $405,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 1.8%

BMY opened at $63.66 on Wednesday. The stock has a market capitalization of $130.05 billion, a price-to-earnings ratio of 14.02, a P/E/G ratio of 0.17 and a beta of 0.22. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $68.10. The company has a 50-day simple moving average of $59.09 and a 200 day simple moving average of $58.80.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analysts’ expectations of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business’s revenue for the quarter was up 5.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.96 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 55.51%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research reports. Royal Bank Of Canada lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Piper Sandler initiated coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued an “overweight” rating on the stock. Guggenheim reissued a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a report on Friday, July 31st. Jefferies Financial Group cut shares of Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Finally, Bank of America decreased their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research note on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average target price of $66.06.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst earnings estimates increased: Erste Group Bank raised its FY2026 EPS forecast for BMY to $6.96 from $6.34, matching the broader consensus, and lifted its FY2027 estimate to $6.51 from $6.10. The revisions suggest improving confidence in the company’s earnings outlook. Bristol Myers Squibb earnings estimate revisions
• Positive Sentiment: $2.3 billion Houston manufacturing campus: BMY plans to build an approximately 600,000-square-foot advanced manufacturing and life sciences facility at Generation Park in Houston. The project is expected to create about 500 permanent jobs and roughly 2,000 construction jobs, expanding the company’s U.S. production capacity and supporting its previously announced $40 billion domestic investment commitment. Bristol Myers to build $2.3 billion manufacturing site in Houston
• Neutral Sentiment: Broker sentiment remains favorable but not strongly bullish: BMY continues to carry an average “Moderate Buy” recommendation. Recent commentary highlights the company’s growth portfolio and pipeline, but also cautions that generic competition and the stock’s prior gains could limit near-term upside. Bristol Myers Squibb receives Moderate Buy recommendation
• Negative Sentiment: Merger speculation is unconfirmed: Reports that BMY held merger discussions with AstraZeneca helped send AZN sharply lower, but neither company confirmed the talks. The lack of confirmation and skepticism from Wall Street may weigh on BMY by raising questions about deal costs, integration risks and strategic priorities, even though a combination would create one of the world’s largest drugmakers. AstraZeneca versus Bristol Myers Squibb merger speculation

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.